Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-1,41%
1 076,13
-15,38
-1,41%
—1 091,511 090,401 090,401 073,69——
SIXC
Communications
SIXC
Communications
SIXC
-0,55%
606,74
-3,37
-0,55%
—610,11610,11610,29606,17——
SIXE
Energy
SIXE
Energy
SIXE
+0,88%
1 248,82
+10,84
+0,88%
—1 237,981 237,831 252,411 225,03——
SIXI
Industrials
SIXI
Industrials
SIXI
-1,17%
1 724,36
-20,35
-1,17%
—1 744,711 740,951 747,291 721,57——
SIXM
Financials
SIXM
Financials
SIXM
-0,72%
635,59
-4,59
-0,72%
—640,18639,92643,19634,73——
SIXR
Staples
SIXR
Staples
SIXR
-0,76%
843,15
-6,43
-0,76%
—849,58845,27851,68839,47——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,55%
216,29
-1,19
-0,55%
—217,48217,48218,16215,51——
SIXT
Technology
SIXT
Technology
SIXT
+0,08%
3 263,41
+2,72
+0,08%
—3 260,693 273,363 287,813 240,78——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,34%
939,24
-3,21
-0,34%
—942,45939,39948,80933,98——
SIXV
Health care
SIXV
Health care
SIXV
-0,29%
1 462,56
-4,24
-0,29%
—1 466,801 464,701 467,191 458,36——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0,71%
2 380,40
-17,10
-0,71%
—2 397,502 395,032 412,012 370,64——
7CA:FRA
Camurus AB
€49,92
+0,52%
(+0,26) 1D
5 Mei, 08:02:05 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 7CA...
Open
€49,92
High
€49,92
Low
€49,92
Mkt. cap
31,56 mjd
Avg. vol.
29,00
Volume
0,00
52-wk high
€67,80
52-wk low
€40,60
No. of employees
285
News stories
From sources across the web
Profile
Camurus AB is a Swedish research-based pharmaceutical and biotechnology company specialising in the commercialization of medicines for treating serious and chronic diseases. Established in 1991 and based in the southern university city of Lund, in the Medicon Valley region, the company is listed on Nasdaq Stockholm, Mid Cap. Camurus was founded by scientists in biophysical, food, and pharmaceutical chemistry with expertise in lipid phase structures. The company provides nanoscale drug-delivery systems for development of high-value therapeutics. Wikipedia
About Camurus AB
CEOFredrik Tiberg
Employees285
Founded1991
Headquarters-
SectorPharmaceutical industry
Websitecamurus.com
Previous reportsAll values in SEK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SEK
Mrt. 2025
Jun. 2025
Sep. 2025
Des. 2025
Revenue
558,34 m
675,50 m
567,07 m
464,46 m
Cost of goods sold
39,29 m
41,14 m
39,33 m
36,38 m
Cost of revenue
39,29 m
41,14 m
39,33 m
36,38 m
Research and development expenses
131,45 m
151,19 m
109,34 m
124,94 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
157,40 m
185,12 m
181,13 m
184,49 m
Operating expense
280,17 m
342,31 m
297,52 m
315,31 m
Total operating expenses
319,46 m
383,45 m
336,85 m
351,68 m
Operating income
238,88 m
292,05 m
230,22 m
112,78 m
Other non operating income
-
-
-
-
EBT including unusual items
253,96 m
307,01 m
245,28 m
126,84 m
EBT excluding unusual items
253,96 m
307,01 m
245,28 m
126,84 m
Income tax expense
56,71 m
62,22 m
52,64 m
25,96 m
Effective tax rate
22,33%
20,27%
21,46%
20,47%
Other operating expenses
-8,69 m
6,00 m
7,05 m
5,88 m
Net income
197,25 m
244,79 m
192,64 m
100,88 m
Net profit margin
35,33%
36,24%
33,97%
21,72%
Earnings per share
3,29
4,08
3,19
1,67
Interest and investment income
16,41 m
16,38 m
16,50 m
15,63 m
Interest expense
-1,34 m
-1,42 m
-1,44 m
-1,57 m
Net interest expenses
15,08 m
14,96 m
15,06 m
14,06 m
Depreciation and amortization charges
-
-
-
-
EBITDA
244,52 m
298,33 m
236,64 m
119,44 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer